FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1971305591> ?p ?o ?g. }

• W1971305591 endingPage "1967" @default.
• W1971305591 startingPage "1961" @default.
• W1971305591 abstract "This phase 1 dose-escalation study determined the maximum tolerated dose (MTD) of oral pomalidomide (4 dose levels) administered on days 1 to 21 of each 28-day cycle in patients with relapsed and refractory multiple myeloma (RRMM). After four cycles, patients who progressed or had not achieved minimal response (serum and urine M-protein reduction of ≥ 25% and ≥ 50%) could receive dexamethasone 40 mg per week. Safety and efficacy were evaluated. Thirty-eight patients who had received both bortezomib and lenalidomide (median 6 prior therapies) were enrolled; 63% were refractory to both lenalidomide and bortezomib. There were four dose-limiting toxicities (grade 4 neutropenia) at 5 mg per day and so the MTD was 4 mg per day. Rates of peripheral neuropathy and venous thromboembolism were low (≤ 5%). Among the 38 patients enrolled (including 22 with added dexamethasone), 42% achieved minimal response or better, 21% achieved partial response or better, and 3% achieved complete response. Median duration of response, progression-free survival, and overall survival were 4.6, 4.6, and 18.3 months, respectively. Pomalidomide 4 mg per day on days 1 to 21 of each 28-day cycle, with or without dexamethasone (40 mg/week), has encouraging activity with manageable toxicity in RRMM, including those refractory to both lenalidomide and bortezomib. This study is registered at http://www.clinicaltrials.gov as #NCT00833833." @default.
• W1971305591 created "2016-06-24" @default.
• W1971305591 creator A5012718640 @default.
• W1971305591 creator A5021617351 @default.
• W1971305591 creator A5023152679 @default.
• W1971305591 creator A5023752321 @default.
• W1971305591 creator A5027328800 @default.
• W1971305591 creator A5028521293 @default.
• W1971305591 creator A5032464400 @default.
• W1971305591 creator A5034381928 @default.
• W1971305591 creator A5036556844 @default.
• W1971305591 creator A5037850152 @default.
• W1971305591 creator A5043526996 @default.
• W1971305591 creator A5043963551 @default.
• W1971305591 creator A5045451441 @default.
• W1971305591 creator A5045740077 @default.
• W1971305591 creator A5048632445 @default.
• W1971305591 creator A5049711954 @default.
• W1971305591 creator A5051627358 @default.
• W1971305591 creator A5058588052 @default.
• W1971305591 creator A5077110117 @default.
• W1971305591 creator A5083373597 @default.
• W1971305591 creator A5086214161 @default.
• W1971305591 creator A5087799564 @default.
• W1971305591 date "2013-03-14" @default.
• W1971305591 modified "2023-09-28" @default.
• W1971305591 title "Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib" @default.
• W1971305591 cites W1968654086 @default.
• W1971305591 cites W1973532909 @default.
• W1971305591 cites W1973888964 @default.
• W1971305591 cites W1975916512 @default.
• W1971305591 cites W1978377409 @default.
• W1971305591 cites W1989740966 @default.
• W1971305591 cites W1992470642 @default.
• W1971305591 cites W2000047150 @default.
• W1971305591 cites W2026742920 @default.
• W1971305591 cites W2044436186 @default.
• W1971305591 cites W2059607379 @default.
• W1971305591 cites W2060496777 @default.
• W1971305591 cites W2066800926 @default.
• W1971305591 cites W2075670392 @default.
• W1971305591 cites W2108235071 @default.
• W1971305591 cites W2118820477 @default.
• W1971305591 cites W2128903704 @default.
• W1971305591 cites W2133986577 @default.
• W1971305591 cites W2135404380 @default.
• W1971305591 cites W2140579395 @default.
• W1971305591 cites W2142149038 @default.
• W1971305591 cites W2147769421 @default.
• W1971305591 cites W2161767400 @default.
• W1971305591 cites W2162468902 @default.
• W1971305591 cites W2224940905 @default.
• W1971305591 cites W4313376856 @default.
• W1971305591 doi "https://doi.org/10.1182/blood-2012-08-450742" @default.
• W1971305591 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4123324" @default.
• W1971305591 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23243282" @default.
• W1971305591 hasPublicationYear "2013" @default.
• W1971305591 type Work @default.
• W1971305591 sameAs 1971305591 @default.
• W1971305591 citedByCount "145" @default.
• W1971305591 countsByYear W19713055912013 @default.
• W1971305591 countsByYear W19713055912014 @default.
• W1971305591 countsByYear W19713055912015 @default.
• W1971305591 countsByYear W19713055912016 @default.
• W1971305591 countsByYear W19713055912017 @default.
• W1971305591 countsByYear W19713055912018 @default.
• W1971305591 countsByYear W19713055912019 @default.
• W1971305591 countsByYear W19713055912020 @default.
• W1971305591 countsByYear W19713055912021 @default.
• W1971305591 countsByYear W19713055912022 @default.
• W1971305591 countsByYear W19713055912023 @default.
• W1971305591 crossrefType "journal-article" @default.
• W1971305591 hasAuthorship W1971305591A5012718640 @default.
• W1971305591 hasAuthorship W1971305591A5021617351 @default.
• W1971305591 hasAuthorship W1971305591A5023152679 @default.
• W1971305591 hasAuthorship W1971305591A5023752321 @default.
• W1971305591 hasAuthorship W1971305591A5027328800 @default.
• W1971305591 hasAuthorship W1971305591A5028521293 @default.
• W1971305591 hasAuthorship W1971305591A5032464400 @default.
• W1971305591 hasAuthorship W1971305591A5034381928 @default.
• W1971305591 hasAuthorship W1971305591A5036556844 @default.
• W1971305591 hasAuthorship W1971305591A5037850152 @default.
• W1971305591 hasAuthorship W1971305591A5043526996 @default.
• W1971305591 hasAuthorship W1971305591A5043963551 @default.
• W1971305591 hasAuthorship W1971305591A5045451441 @default.
• W1971305591 hasAuthorship W1971305591A5045740077 @default.
• W1971305591 hasAuthorship W1971305591A5048632445 @default.
• W1971305591 hasAuthorship W1971305591A5049711954 @default.
• W1971305591 hasAuthorship W1971305591A5051627358 @default.
• W1971305591 hasAuthorship W1971305591A5058588052 @default.
• W1971305591 hasAuthorship W1971305591A5077110117 @default.
• W1971305591 hasAuthorship W1971305591A5083373597 @default.
• W1971305591 hasAuthorship W1971305591A5086214161 @default.
• W1971305591 hasAuthorship W1971305591A5087799564 @default.
• W1971305591 hasBestOaLocation W19713055911 @default.
• W1971305591 hasConcept C121332964 @default.
• W1971305591 hasConcept C126322002 @default.
• W1971305591 hasConcept C126894567 @default.

• next